



**Survey of General Medical Oncologists:  
November 22<sup>nd</sup> – December 5<sup>th</sup>**

# Chronic Myeloid Leukemia (CML)

# Topics of Interest for Future CME Programs



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to front-line treatment for patients with CP-CML?




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the similarities and differences among imatinib, dasatinib, nilotinib and bosutinib?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the recent FDA approval and the mechanism of action of asciminib?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the comparison of asciminib to TKI therapy as front-line treatment for CP-CML?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the rationale for combining asciminib and TKI therapy for CP-CML?



Well informed

Uninformed



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to available therapeutic options for relapsed CP-CML with and without a T315I mutation?




Well informed

Uninformed

# Acute Myeloid Leukemia (AML)

# Topics of Interest for Future CME Programs



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to treatment for older patients with newly diagnosed AML?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the selection of initial therapy for younger patients with AML and no targetable mutations?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the role of FLT3 inhibitors in the management of AML (eg, gilteritinib, quizartinib)?




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the incorporation of IDH inhibitors in the treatment of AML (eg, ivosidenib, enasidenib, olutasidenib)?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to available efficacy and safety data with menin inhibitors (eg, revumenib, ziftomenib)?




Well informed

Uninformed



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the rationale for targeting CD123 in AML and the mechanism of action of pivekimab sunirine?




Well informed


Uninformed

# Chronic Lymphocytic Leukemia (CLL)

# Topics of Interest for Future CME Programs




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the selection of first-line therapy for newly diagnosed CLL requiring treatment?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the optimal BTK inhibitor in the first-line setting?



Well informed


Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the rationale for combining BTK inhibitors with Bcl-2 inhibitors?




Well informed Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to sequencing BTK inhibitors for relapsed/refractory CLL?



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to similarities and differences between venetoclax and sonrotoclax?




Well informed

Uninformed



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to novel doublet and triplet combinations of BTK inhibitors and Bcl-2 inhibitors under investigation?




Well informed


Uninformed

# Myelofibrosis (MF)

# Topics of Interest for Future CME Programs




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the choice and initiation of therapy for patients with MF without severe cytopenias?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to therapy for patients with MF and thrombocytopenia?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to therapy for patients with MF and anemia?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the rationale for the evaluation of selinexor for MF?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the mechanism of action of imetelstat and its potential role in the treatment of MF?



Well informed Uninformed



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to other promising investigational agents and strategies for MF (eg, zilurgisertib, navtemadlin)?



Well informed

Uninformed